Atlas Trials

Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma

Clinical trial NCT07355699 · RECRUITING

Trial details

NCT number
NCT07355699
Sponsor
Beijing Tongren Hospital
Status
RECRUITING
Phase
Phase 4
Study type
INTERVENTIONAL
Marginal Zone Lymphoma(MZL)
Start date
2025-11-25
Primary completion
2027-09-30
Enrollment
88

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.